Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
2.
Urologe A ; 33(2): 133-7, 1994 Mar.
Article in German | MEDLINE | ID: mdl-8178407

ABSTRACT

A total of 78 patients with superficial bladder carcinoma were prospectively randomized to two groups following complete transurethral resection (TUR). Each received 12 intravesical instillations of 10(7) units interferon A or 120 mg BCG Connaught for 1 year starting 6 weeks post-TUR. After a mean observation period of 24 (13-31) months in the BCG and 25 (6-32) months in the IFN group 5/32 (15.6%) recurrences in the BCG versus 21/35 (60%) in the IFN group were observed (P = 0.0003). In the IFN group 18.4% of the patients had dysuria and 2.6% fever; in the BCG group 35% had fever, 60% cystitis, 1 patient granulomatous epididimoorchitis and 1 patient pneumonitis with granulomatous prostatitis. With our instillation regimen interferon A had few side effects but also no prophylactic effect, whereas BCG had tolerable-seldom severe--side effects and was very effective in preventing recurrences. Perhaps IFN should be given earlier after TUR and in a higher dosage.


Subject(s)
BCG Vaccine/administration & dosage , Carcinoma, Transitional Cell/therapy , Interferon-alpha/administration & dosage , Neoplasm Recurrence, Local/therapy , Urinary Bladder Neoplasms/therapy , Administration, Intravesical , BCG Vaccine/adverse effects , Carcinoma, Transitional Cell/pathology , Combined Modality Therapy , Dose-Response Relationship, Drug , Drug Administration Schedule , Electrocoagulation , Follow-Up Studies , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Prospective Studies , Recombinant Proteins , Urinary Bladder Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...